Dutasteride/tamsulosin

Dutasteride/tamsulosin, sold under the brand name Jalyn among others, is a medication produced by GlaxoSmithKline for the treatment of adult male symptomatic benign prostatic hyperplasia (BPH).^[3] It is a combination of two previously existing medications: dutasteride, brand name Avodart, and tamsulosin, brand name Flomax. It contains 0.5 mg of dutasteride and 0.4 mg of tamsulosin hydrochloride.^[2]

Dutasteride/tamsulosin

Combination of
Dutasteride	5α-Reductase inhibitor
Tamsulosin	Alpha-1 blocker
Clinical data
Trade names	Jalyn
AHFS/Drugs.com	Professional Drug Facts
License data	US DailyMed: Dutasteride_and_tamsulosin
Pregnancy category	AU: X (High risk)
Routes of administration	By mouth
ATC code	G04CA52 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)[1] US: ℞-only[2]
Identifiers
CAS Number	2227979-41-9
KEGG	D11389

Jalyn was the result of the CombAT (Combination of Avodart and Tamsulosin) trial of 2008. It was approved by the U.S. Food and Drug Administration (FDA) on June 14, 2010.^[4] In June 2011, the FDA approved a label change to warn of "Increased Risk of High-grade Prostate Cancer" from Jalyn.^[5]